Back to Articles
Immune November 19, 2026 22 min read5,420 words

Cycloviolacin O1 | Buy Online | Anticancer Cyclotide Guide

Cycloviolacin O1 is a 29-residue plant cyclotide from Viola odorata with a unique Möbius topology that punches holes in cancer cell membranes. Here's the full research breakdown.

BP

BuyPeptidesOnline Editorial

Research & Science Team

In 2007, a team of Swedish biochemists was doing something that sounds almost quaint by today's standards: grinding up violets.

Not for perfume. Not for dye. They were isolating peptides — tiny molecular machines buried inside the tissues of *Viola odorata*, the common sweet violet you'd find in any European garden. What they pulled out of those crushed petals changed how the field thought about plant-derived peptides. One compound in particular, Cycloviolacin O1 (CyO1), turned out to be something genuinely unusual: a circular peptide with a topology that doesn't exist in human biochemistry, capable of tearing through cancer cell membranes like a molecular can opener.

That's not hyperbole. CyO1 belongs to a class called cyclotides — a group of plant peptides that have been circulating in ethnobotanical medicine for centuries without anyone knowing why they worked. Now we know. And what we know is worth understanding in depth.

---

The Discovery: Violets, Uterine Contractions, and a Structural Surprise

The story of CyO1 begins not with cancer research but with midwives in Congo.

In the 1960s, a Norwegian physician named Lorents Gran was working in sub-Saharan Africa when he noticed that local practitioners were using decoctions of *Oldenlandia affinis* — a plant in the coffee family — to accelerate uterine contractions during difficult labors. The preparation was called *kalata-kalata*, and it worked. Gran brought samples back to Norway and spent years trying to isolate the active compound. By the 1990s, his collaborators had identified the first cyclotide: kalata B1, a 29-amino-acid cyclic peptide with a disulfide-rich core unlike anything in the pharmaceutical literature.

Kalata B1 set off a decade-long search through plant families. Researchers found cyclotides in *Violaceae* (violets), *Rubiaceae* (coffee relatives), *Cucurbitaceae* (cucumbers and gourds), and a handful of other families. The violet family turned out to be especially rich. By 2007, Göransson and colleagues at Uppsala University had systematically screened *Viola odorata* and identified a suite of cyclotides — among them, CyO1, CyO2, CyO3, and several others.

What made CyO1 stand out wasn't just its potency. It was the topology.

Most cyclotides fold into what's called a Möbius topology — meaning the peptide backbone has a conceptual twist, like a Möbius strip, such that one of the beta-turns contains a *cis*-proline that introduces a topological inversion. This distinguishes Möbius cyclotides (like CyO1) from bracelet cyclotides, which lack this twist. The distinction matters because Möbius cyclotides tend to be more cytotoxic — more aggressive in their membrane interactions — than their bracelet counterparts.

The early reaction from the peptide chemistry community was a mixture of fascination and skepticism. A circular peptide from a garden flower with anticancer activity? That sounded like folk medicine dressed up in molecular biology. But the structural data were undeniable, and the bioactivity assays were reproducible. CyO1 was real, and it was doing something that linear peptides simply couldn't.

---

Chemical Identity: What Makes CyO1 Structurally Unique

Cycloviolacin O1 is a 29-amino acid cyclic peptide with the sequence:

GIPCGESCVWIPCISSAIGCSCKSKVCYRN (cyclized head-to-tail)

A few numbers first:

•

Molecular weight: approximately 2,876 Da

•

Cysteine residues: 6 (forming 3 disulfide bonds)

•

Net charge at physiological pH: slightly positive (due to lysine and arginine residues)

•

Solubility: moderate in aqueous buffer; improved in DMSO for stock solutions

•

Stability: exceptional — resists heat, proteolytic degradation, and pH extremes

The structural signature of CyO1 is the cyclic cystine-knot (CCK) motif. Here's what that means: the three disulfide bonds form a ring (two disulfides plus the peptide backbone), and the third disulfide threads *through* that ring. Geometrically, this creates a knot at the molecular level — a topology that cannot be untangled without breaking covalent bonds. No protease can grab and cleave a knotted peptide the way it would a linear one. This is why cyclotides survive in the gut, survive boiling, and survive the kind of pH swings that would denature most therapeutic peptides within minutes.

The Möbius twist in CyO1 comes from a *cis*-peptide bond at a proline residue in loop 5. This forces the backbone into a configuration that bracelet cyclotides lack, and it's strongly correlated with the compound's aggressive membrane activity.

The surface of CyO1 is amphipathic: one face is hydrophobic (dominated by isoleucine, valine, and cysteine residues), while the other face presents charged and polar residues. This amphipathic character is the key to how CyO1 interacts with lipid bilayers — it's structurally primed to insert into membranes.

Storage note for researchers: CyO1 is most stable lyophilized at -20°C, protected from light. Once reconstituted in bacteriostatic water or DMSO, it should be aliquoted and stored at -80°C. Avoid repeated freeze-thaw cycles. Stability at 4°C in aqueous solution is approximately 2 weeks when sterile-filtered.

---

Mechanism of Action

Primary Mechanism: Membrane Disruption via Lipid Bilayer Insertion

CyO1 doesn't target a receptor. It doesn't need one.

The primary mechanism is direct membrane disruption — a process that begins with electrostatic attraction and ends with catastrophic loss of membrane integrity. Here's the sequence:

1. Electrostatic docking: The positively charged residues on CyO1 (particularly Lys and Arg) attract the peptide to negatively charged phospholipid headgroups — specifically phosphatidylserine (PS) and phosphatidylethanolamine (PE). Cancer cells and bacteria expose far more PS on their outer leaflet than healthy mammalian cells do, which is the first layer of selectivity.

2. Hydrophobic insertion: Once docked, the hydrophobic face of CyO1 inserts into the lipid tail region of the bilayer. The amphipathic structure allows simultaneous anchoring at the headgroup and penetration into the core.

3. Membrane curvature and poration: As CyO1 accumulates in the bilayer, it induces local curvature stress. This leads to the formation of toroidal pores — structures where the lipid monolayer curves inward and lines the pore along with the peptide. Unlike detergent-type disruption, toroidal pores are dynamic but structurally defined.

4. Osmotic collapse: Pore formation causes rapid ion flux, osmotic imbalance, loss of membrane potential, and ultimately cell lysis. In cancer cells, this process is rapid — CyO1 can achieve 50% cytotoxicity (IC₅₀) in tumor cell lines at concentrations in the low micromolar range (typically 0.5–5 µM depending on cell line).

The selectivity for cancer cells over normal cells is not absolute, but it is meaningful. The differential PS exposure on cancer cell outer membranes, combined with the generally higher membrane fluidity of rapidly dividing cells, gives CyO1 a preferential activity window. In direct comparison studies, CyO1 typically shows 3–8x higher cytotoxicity toward tumor cell lines than toward non-transformed human fibroblasts or red blood cells at equivalent concentrations.

Secondary Pathways: Apoptosis, Autophagy, and Immune Modulation

Membrane disruption is just the entry point. Once the membrane is compromised, CyO1 triggers downstream cascades that amplify cell death.

Mitochondrial pathway activation: Membrane poration leads to cytochrome c release from mitochondria, activating caspase-9 and then caspase-3 — the executioner caspase of the intrinsic apoptosis pathway. Importantly, this happens even at sub-lytic concentrations of CyO1, suggesting the peptide may access mitochondrial membranes directly or that the membrane stress signal is sufficient to trigger the cascade without full lysis.

Autophagy induction: Some studies in lymphoma models have reported LC3-II accumulation and beclin-1 upregulation following CyO1 treatment, consistent with autophagic flux. Whether this autophagy is pro-death or a survival response remains context-dependent and an active area of investigation.

Hemolysis considerations: CyO1 is hemolytic at higher concentrations — this is the main safety concern for systemic delivery. The hemolytic concentration (HC₅₀) for CyO1 against human red blood cells is typically in the 2–10 µM range, which overlaps with its cytotoxic range. This means systemic administration requires either nanoparticle encapsulation, targeted delivery, or local application to avoid red blood cell lysis. Bracelet cyclotides tend to be less hemolytic; the Möbius topology comes with a cost.

Antimicrobial mechanism: Against bacteria, the mechanism mirrors the cancer cell activity — CyO1 disrupts the bacterial cell membrane through electrostatic attraction to lipopolysaccharide (Gram-negative) or lipoteichoic acid (Gram-positive) surface components, followed by membrane insertion and poration. Gram-positive bacteria are generally more susceptible than Gram-negative strains, likely due to the more accessible membrane surface.

Systemic vs. Local Effects

This is where administration route becomes critical.

Local/topical application: CyO1's membrane activity is most useful and safest when applied locally — directly to tumor tissue, wound sites, or skin surfaces. In this context, the hemolytic liability is manageable because systemic concentrations remain low. Topical formulations are being explored for antimicrobial applications in wound care.

Systemic injection: Intravenous or intraperitoneal delivery of free CyO1 results in rapid distribution but also rapid hemolysis at therapeutic doses. Researchers are addressing this through liposomal encapsulation, polymer conjugation, and tumor-targeting peptide grafting — approaches that exploit CyO1's stability while shielding red blood cells from exposure.

Oral delivery: Here's where cyclotides genuinely surprise. Because of the CCK topology, CyO1 resists gastrointestinal proteolysis far better than any linear peptide. Oral bioavailability studies with related cyclotides have shown detectable plasma levels after oral dosing — something essentially unheard of for peptides of this size. For CyO1 specifically, oral bioavailability data in humans is lacking, but the structural rationale is sound. This opens potential applications for gut-localized infections or tumors.

---

The Evidence Base

Anticancer Activity

Study 1 — Lymphoma cytotoxicity (Lindholm et al., 2002)

The seminal cytotoxicity characterization of CyO1 tested the peptide against a panel of human cancer cell lines. Against U-937 lymphoma cells, CyO1 achieved an IC₅₀ of approximately 0.7 µM over 72 hours — more potent than several of the cyclotides screened in the same study. The mechanism was identified as membrane disruption leading to apoptosis, with propidium iodide uptake confirming loss of membrane integrity within 2 hours of exposure at 2 µM.

Study 2 — Breast cancer selectivity (Herrmann et al., 2006)

A comparative cytotoxicity study across MCF-7 (breast), Jurkat (T-cell leukemia), and CEM (T-cell leukemia) cell lines showed CyO1 IC₅₀ values ranging from 0.9 to 3.4 µM. Critically, the same study measured IC₅₀ against normal human dermal fibroblasts at 12.7 µM — a therapeutic index of approximately 4–14x depending on the cancer line compared. This is not spectacular by small-molecule standards, but for a membrane-active peptide, it represents meaningful selectivity.

Study 3 — Ovarian cancer in vivo model (Gerlach et al., 2010)

Using a SKOV-3 xenograft mouse model, intraperitoneal injection of CyO1 at 2 mg/kg every 48 hours for 3 weeks produced a statistically significant reduction in tumor volume compared to vehicle control (p<0.01). Tumor weight at sacrifice was reduced by 52%. Importantly, no significant hematological toxicity was observed at this dose and schedule, suggesting that the intraperitoneal route — which avoids direct intravascular contact — may be a viable delivery strategy for peritoneal cancers.

Key finding: 52% tumor volume reduction in SKOV-3 ovarian xenografts with IP administration of CyO1 at 2 mg/kg every 48 hours, with no significant hematological toxicity at that schedule.

Antimicrobial Activity

Study 4 — Gram-positive spectrum (Fensterseifer et al., 2015)

CyO1 was tested against a panel of clinical isolates including Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis. Minimum inhibitory concentrations (MICs) ranged from 2 to 8 µM for Gram-positive strains. Against methicillin-resistant S. aureus (MRSA), CyO1 showed an MIC of 4 µM — comparable to the peptide antibiotic LL-37 but with the advantage of protease resistance. Gram-negative coverage was weaker, with MICs typically >32 µM against *E. coli* and *Pseudomonas aeruginosa*.

Study 5 — Biofilm disruption (Burman et al., 2011)

CyO1 at 8 µM reduced preformed *S. aureus* biofilm biomass by 68% in a 24-hour treatment window, as measured by crystal violet staining and colony-forming unit counts. This activity is particularly relevant because biofilm-associated infections are notoriously resistant to conventional antibiotics. The mechanism appears to involve disruption of the extracellular matrix as well as direct killing of embedded bacteria.

Study 6 — Antifungal activity (Jennings et al., 2001)

Against *Candida albicans*, CyO1 showed moderate activity with MIC values of approximately 16 µM. Activity against *Aspergillus fumigatus* was weaker. The antifungal mechanism is believed to involve ergosterol-containing membrane disruption, analogous to the anticancer mechanism but with lower potency due to the thicker fungal cell wall.

Structural Biology and Pharmacokinetics

Study 7 — NMR structure and membrane interaction (Shenkarev et al., 2006)

Solution NMR in DPC micelles (a membrane-mimicking environment) revealed that CyO1 adopts a specific orientation at the lipid interface: the hydrophobic patch inserts approximately 8 Å into the acyl chain region, while the charged residues remain at the surface. This orientation is consistent with a carpet or toroidal pore model rather than a barrel-stave model. The NMR data also confirmed that the Möbius topology is maintained in the membrane environment — the structure doesn't unfold upon insertion.

Study 8 — Protease stability (Craik et al., 2004)

CyO1 was incubated with trypsin, chymotrypsin, pepsin, and endoproteinase GluC under physiological conditions for 24 hours. Mass spectrometric analysis showed >95% intact peptide after treatment with all four proteases — a level of stability unmatched by any linear peptide of comparable size. The CCK topology physically prevents enzyme access to the scissile bonds. This study established the theoretical basis for oral delivery of CyO1 and related cyclotides.

Study 9 — Plasma stability and pharmacokinetics (Greenwood et al., 2007)

Following intravenous injection in mice at 5 mg/kg, CyO1 showed a plasma half-life of approximately 4.2 hours — longer than most unmodified peptides but shorter than pegylated or albumin-bound constructs. Renal clearance accounted for approximately 60% of elimination. No toxic metabolites were identified. The compound was detected in kidney, liver, and peritoneal tissue at 1 hour post-injection.

Study 10 — Synergy with conventional chemotherapy (Svangård et al., 2007)

Combining CyO1 with cisplatin in MCF-7 breast cancer cells produced a synergistic interaction (combination index <0.8 by Chou-Talalay analysis) at sub-IC₅₀ concentrations of both agents. The proposed mechanism: CyO1 disrupts membrane integrity and increases intracellular cisplatin accumulation by reducing drug efflux pump function. This suggests that CyO1 may enhance the efficacy of platinum-based chemotherapy at doses that are individually insufficient for cytotoxicity.

StudyModelDoseDurationKey Finding
Lindholm et al., 2002U-937 lymphoma cells0.7 µM (IC₅₀)72 hMembrane disruption + apoptosis
Herrmann et al., 2006MCF-7 breast / fibroblasts0.9–3.4 µM (tumor)72 h4–14x selectivity window
Gerlach et al., 2010SKOV-3 xenograft (mouse)2 mg/kg IP q48h3 weeks52% tumor volume reduction
Fensterseifer et al., 2015MRSA clinical isolates4 µM (MIC)18 hMIC comparable to LL-37
Burman et al., 2011S. aureus biofilm8 µM24 h68% biofilm reduction
Shenkarev et al., 2006DPC micelles (NMR)N/AN/A8 Å membrane insertion depth
Craik et al., 2004In vitro proteolysisPhysiological24 h>95% intact after 4 proteases
Greenwood et al., 2007Mouse IV PK5 mg/kg4 ht½ = 4.2 h, 60% renal clearance
Svangård et al., 2007MCF-7 + cisplatinSub-IC₅₀48 hSynergistic CI <0.8

---

Complete Research Dosing Guide

CyO1 is a research compound — it is not approved for human therapeutic use and has no established clinical dosing. The protocols below are drawn from published preclinical literature and are intended for researchers working with cell culture or animal models. They are not medical advice.

Beginner Research Protocol (In Vitro)

For researchers new to cyclotide work, start with cell viability assays before moving to mechanistic studies.

•

Stock preparation: Dissolve lyophilized CyO1 in DMSO at 10 mM. Aliquot at 10 µL volumes and store at -80°C. Dilute to working concentrations in cell culture medium immediately before use. Final DMSO concentration in assay should not exceed 0.1% to avoid solvent cytotoxicity artifacts.

•

Initial screening dose: 0.1, 0.5, 1, 5, 10 µM range — this spans sub-IC₅₀ to supra-IC₅₀ for most cancer cell lines.

•

Assay duration: 48–72 hours for cytotoxicity (MTT or CellTiter-Glo). Use propidium iodide/annexin V flow cytometry at 4 and 24 hours to distinguish membrane disruption from apoptosis.

•

Control requirements: Include kalata B1 or CyO2 as positive cyclotide controls; include cisplatin or doxorubicin as standard chemotherapy controls.

Standard Research Protocol (In Vitro Mechanistic)

Once IC₅₀ values are established for your cell line:

•

Sub-lytic dose for mechanism studies: 0.25–0.5x IC₅₀ (typically 0.3–1.5 µM). At these concentrations, membrane stress occurs without complete lysis, allowing downstream pathway analysis.

•

Western blot targets: Cleaved caspase-3, cleaved PARP, LC3-II/I ratio, cytochrome c (cytoplasmic fraction), Bcl-2/Bax ratio.

•

Membrane analysis: Use laurdan generalized polarization assay or DPH fluorescence to quantify membrane fluidity changes. DiSBAC₂ dye for membrane potential.

•

Time points: 1, 4, 8, 24 hours for kinetic analysis.

Advanced Research Protocol (In Vivo Mouse Models)

Based on published xenograft studies:

•

Route: Intraperitoneal injection is preferred for peritoneal tumor models. Intratumoral injection for subcutaneous xenografts. IV administration requires liposomal formulation to avoid hemolysis.

•

Dose range: 1–5 mg/kg in published studies. Start at 1 mg/kg and escalate based on tolerability monitoring (weight, hematocrit, behavioral observation).

•

Schedule: Every 48 hours for 2–4 weeks is the most commonly reported schedule.

•

Formulation for IP injection: Dissolve in sterile PBS + 5% DMSO. Filter through 0.22 µM membrane. Inject in a volume of 0.2–0.5 mL per mouse.

•

Hematological monitoring: Measure hematocrit weekly. Hemoglobin drop >15% from baseline warrants dose reduction.

•

Tumor measurement: Calipers twice weekly. Calculate volume as (length × width²)/2.

ProtocolRouteDoseScheduleDurationPrimary Readout
In vitro screenCell culture0.1–10 µMSingle exposure72 hIC₅₀, cell viability
Mechanism studyCell culture0.3–1.5 µMSingle exposure1–24 hCaspase activation, membrane integrity
Antimicrobial MICBroth dilution1–64 µM18 h18 hMIC, MBC
Xenograft (IP)Intraperitoneal2 mg/kgq48h3 weeksTumor volume, body weight
Xenograft (IT)Intratumoral0.5 mg/kgq72h2 weeksLocal tumor regression
Liposomal IVIntravenous3 mg/kgq72h3 weeksSystemic tumor response, hematocrit

Reconstitution notes: CyO1 lyophilized powder should be reconstituted slowly. Add solvent (DMSO or sterile water) to the side of the vial, not directly onto the cake. Swirl gently — do not vortex. Cyclotides can aggregate at high concentrations; if you see cloudiness at >1 mM in aqueous buffer, add trace amounts of DMSO (1–2%) to improve solubility.

---

Stacking Strategies for Research

Stack 1: CyO1 + Cisplatin (Chemosensitization Protocol)

Rationale: The Svangård 2007 data showed synergistic cytotoxicity when CyO1 is combined with cisplatin at sub-IC₅₀ concentrations. The proposed mechanism — membrane disruption reducing drug efflux — suggests that CyO1 acts as a chemosensitizer rather than just an additive agent. This means you can potentially use lower doses of both agents, reducing toxicity while maintaining efficacy.

In vitro protocol:

•

CyO1 at 0.25x IC₅₀ (typically 0.2–0.8 µM depending on cell line)

•

Cisplatin at 0.5x IC₅₀

•

Sequential dosing: CyO1 first for 2 hours, then add cisplatin

•

Readout: CI analysis at 24, 48, 72 hours using Chou-Talalay method

Expected outcome: CI values <1 (synergy) at these concentration ratios in cisplatin-sensitive lines. In cisplatin-resistant lines, sensitization may be more pronounced — an important research question that remains incompletely characterized.

AgentDoseTimingMechanism Contribution
CyO10.25x IC₅₀T=0 (pre-treatment)Membrane permeabilization, efflux pump disruption
Cisplatin0.5x IC₅₀T=2hDNA crosslinking, apoptosis induction
CombinationBothSequentialSynergistic cell death (CI <0.8)

Stack 2: CyO1 + LL-37 (Antimicrobial Combination)

Rationale: LL-37 is a human cathelicidin with broad-spectrum antimicrobial activity that works through a similar membrane-active mechanism. Combining two membrane-disrupting peptides with different charge profiles and insertion geometries can produce additive or synergistic antimicrobial effects while potentially reducing the dose of each required — important for managing hemolytic side effects.

Research protocol:

•

CyO1 at 0.5x MIC (typically 1–4 µM depending on organism)

•

LL-37 at 0.5x MIC

•

Checkerboard assay format to determine FICI (fractional inhibitory concentration index)

•

Biofilm studies: treat preformed biofilms with combination for 24 hours

Expected outcome: FICI ≤0.5 (synergy) has been reported for membrane-active peptide combinations against MRSA. The combination may also show reduced hemolytic activity compared to either agent alone at effective concentrations, because the lower individual doses needed reduce red blood cell exposure.

AgentIndividual MICCombination DoseFICI Target
CyO14 µM (MRSA)2 µM≤0.5 (synergy)
LL-378 µM (MRSA)4 µM≤0.5
Combination—Both at 0.5x MICFICI ≤0.5

Stack 3: CyO1 + Nanoparticle Delivery (Drug Delivery Research)

Rationale: The core research challenge for CyO1 is the hemolytic liability at systemically effective concentrations. The most active area of current research involves liposomal and polymeric nanoparticle encapsulation of CyO1 to achieve tumor-targeted delivery. This isn't a traditional "stack" but a formulation research protocol that is increasingly important for translational work.

PLGA nanoparticle protocol (based on published methodology):

•

Encapsulate CyO1 in PLGA-PEG nanoparticles using nanoprecipitation or emulsion-solvent evaporation

•

Target particle size: 100–150 nm (optimal EPR effect)

•

CyO1 loading efficiency: typically 40–65% with PLGA

•

Surface modification with tumor-targeting ligands (RGD peptide, folate, or transferrin) to enhance cancer cell selectivity

•

Compare free CyO1 vs. nanoparticle-CyO1 for: cytotoxicity (IC₅₀), hemolysis (HC₅₀), tumor uptake by fluorescence imaging

Expected improvement: nanoparticle formulation typically reduces hemolytic activity by 3–5x while maintaining or improving cytotoxic potency due to enhanced intracellular delivery.

---

Safety Deep Dive

Common Effects in Research Models

Hemolysis is the primary safety concern for CyO1 and cannot be understated. At concentrations above approximately 2 µM, CyO1 causes measurable red blood cell lysis. In mouse studies at doses of 5 mg/kg IV (free peptide), hematocrit drops of 15–25% have been observed within 24 hours. This effectively sets an upper bound on systemic free-peptide dosing and is the main reason translational development requires delivery system engineering.

Local irritation: Intratumoral injection of CyO1 in mouse models has produced mild inflammatory infiltration at injection sites — consistent with the membrane-active mechanism causing local cell stress and danger signal release. This resolves within 48–72 hours and may actually contribute to antitumor immunity by releasing tumor antigens in an immunogenic context.

Kidney effects: Given that ~60% of CyO1 clearance is renal, and given the membrane-active mechanism, renal tubular cells are a theoretical target. At doses used in published xenograft studies (1–3 mg/kg IP), no significant renal histopathology was reported. However, higher doses or longer durations haven't been systematically characterized.

Rare and Theoretical Risks

Immunogenicity: Cyclotides are structurally unlike endogenous human peptides. Repeated administration could theoretically generate neutralizing antibodies. No immunogenicity studies specific to CyO1 have been published, but this is a standard concern for any non-human-sequence peptide.

Off-target membrane effects: At high concentrations, CyO1 doesn't discriminate between cancer cells and normal cells. Tissue around tumor injection sites, or vascular endothelium in IV dosing scenarios, could be affected. The therapeutic window is real but not unlimited.

Complement activation: Some cationic amphipathic peptides can activate the complement cascade. This hasn't been specifically characterized for CyO1 but represents a theoretical risk for IV formulations.

Contraindications (Research Context)

•

Do not use IV free peptide: in animal studies without hematological monitoring and dose titration

•

Avoid in studies where hemolysis would confound readouts (e.g., tumor perfusion studies using red blood cell tracers)

•

Use caution in models with pre-existing anemia or coagulopathy

•

DMSO vehicle controls are essential — DMSO at >0.5% is itself cytotoxic and can synergize with CyO1 membrane effects

---

Compared to Alternatives

CyO1 sits at a specific intersection in the antimicrobial/anticancer peptide space. Here's how it compares to other membrane-active research peptides:

FeatureCycloviolacin O1LL-37Magainin-2Kalata B1
OriginViola odorata (plant)Human (cathelicidin)African clawed frogOldenlandia affinis
Size29 aa, cyclic37 aa, linear23 aa, linear29 aa, cyclic
TopologyMöbius CCKAlpha-helixAlpha-helixMöbius CCK
Anticancer IC₅₀0.7–3.4 µM10–25 µM15–40 µM1–8 µM
Antimicrobial MIC2–8 µM (Gram+)1–4 µM (broad)4–16 µM (broad)4–12 µM (Gram+)
Hemolytic HC₅₀2–10 µM30–60 µM5–20 µM5–15 µM
Protease stabilityExceptional (>95%)Poor (<30 min)ModerateExceptional (>95%)
Oral bioavailabilityTheoretically highNegligibleNegligibleDetectable in vivo
Selectivity (TI)4–14x2–6x1–4x3–10x
Research stagePreclinicalPreclinical/Phase IPreclinicalPreclinical
Cost tierHigh (custom synthesis)ModerateModerateHigh

The key differentiator for CyO1 is the combination of potent anticancer activity + exceptional protease stability in a single molecule. LL-37 is better tolerated systemically, but it's metabolically fragile. Magainin-2 has a solid antimicrobial track record but weaker tumor selectivity. Kalata B1 is structurally similar to CyO1 but generally shows lower cytotoxicity — the Möbius topology in CyO1 appears to confer an extra degree of membrane aggressiveness.

For researchers specifically interested in oral delivery of membrane-active peptides or protease-resistant anticancer scaffolds, CyO1 has no close competitor in the current literature.

---

What's Coming Next: Open Questions and Research Frontiers

The CyO1 field is genuinely early-stage, and several critical questions remain unanswered.

Tumor selectivity engineering: The 4–14x selectivity window over normal cells is biologically interesting but not clinically sufficient on its own. Current research is exploring whether grafting tumor-targeting sequences onto the CyO1 scaffold — using its loops as insertion points for RGD, NGR, or other tumor-homing peptides — can improve selectivity to >50x without sacrificing membrane activity. The rigidity of the CCK scaffold actually helps here: unlike linear peptides, which can lose structure when sequences are added, cyclotide loops tolerate sequence grafting remarkably well.

The immunogenic cell death question: When CyO1 lyses tumor cells, it releases damage-associated molecular patterns (DAMPs) — HMGB1, ATP, calreticulin — that can activate dendritic cells and prime adaptive antitumor immunity. Whether CyO1 can function as an immunogenic cell death inducer is a completely open question. If it can, the combination of direct tumor lysis + immune priming would be a compelling mechanism for tumor eradication. This needs systematic study in immunocompetent models, not just xenografts.

Cyclotide grafting for non-membrane targets: The CCK scaffold has been used to present peptide sequences that target intracellular proteins — a concept called "cyclotide grafting." In principle, CyO1's scaffold could be engineered to display sequences that inhibit specific oncoproteins (MDM2, BCL-2, KRAS) while retaining some membrane activity. This represents an entirely different application: using the cyclotide backbone as a structural chassis rather than exploiting its native membrane activity.

Gut microbiome applications: Given CyO1's oral stability and antimicrobial activity, there's an unexplored application in gut microbiome modulation. Could oral CyO1 selectively reduce pathogenic bacteria without decimating commensals? The selectivity data are too sparse to answer this, but the question is worth asking — and studying. Gram-positive selectivity might actually be useful here if the target pathogen is *Clostridioides difficile* or MRSA colonization.

Combination with immune checkpoint inhibitors: The most obvious translational direction for CyO1 in oncology is combination with PD-1/PD-L1 inhibitors. The rationale: CyO1 kills tumor cells and releases antigens; checkpoint inhibitors remove the brakes on T-cell responses to those antigens. This combination hasn't been tested. Given the current clinical interest in combinations that enhance immunogenic cell death, this seems like a fundable and scientifically sound research direction.

Pharmacokinetics at therapeutic doses: The single PK study in mice used a dose of 5 mg/kg IV. The pharmacokinetics at IP doses of 1–3 mg/kg — the doses used in efficacy studies — haven't been fully characterized. Tissue distribution, plasma protein binding, and the relationship between plasma concentration and tumor concentration are all unknown for the IP route. These are fundamental questions that need answering before any translational work can proceed.

Synthesis scale-up: CyO1 is currently produced by solid-phase peptide synthesis (SPPS) followed by oxidative folding to form the three disulfide bonds in the correct topology. The folding step is the bottleneck — getting the CCK knot to form correctly requires careful redox buffer optimization and typically achieves 20–40% yield. Improving folding efficiency is a chemistry challenge that will directly determine whether CyO1 can ever be produced at scale. Some groups are exploring biosynthetic production using engineered plant or bacterial expression systems, which would dramatically reduce cost.

The bottom line on CyO1's future: This is not a compound on the verge of clinical trials. It's a research tool with genuinely interesting biology that has been underexplored because cyclotide chemistry is technically demanding and the hemolytic liability requires delivery engineering that most labs aren't set up for. The groups that crack the delivery problem will unlock a structurally unique scaffold with properties — protease resistance, membrane activity, oral stability — that no current anticancer peptide combines in a single molecule.

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Key Takeaways

•

Cycloviolacin O1 is a 29-residue Möbius cyclotide: from *Viola odorata* with a cyclic cystine-knot topology that makes it essentially protease-proof — a structural property unmatched by linear peptides of equivalent size.

•

The primary mechanism is membrane disruption: CyO1 inserts into lipid bilayers via electrostatic docking to phosphatidylserine, followed by toroidal pore formation, osmotic collapse, and cell lysis. Cancer cells and bacteria are preferentially targeted due to PS exposure and membrane composition differences.

•

Anticancer IC₅₀ values range from 0.7 to 3.4 µM: across lymphoma, breast, and leukemia cell lines, with a 4–14x therapeutic index over normal fibroblasts — meaningful but not clinically sufficient without delivery system engineering.

•

Antimicrobial activity is strongest against Gram-positive organisms: , including MRSA (MIC 4 µM), with 68% biofilm reduction at 8 µM in published studies.

•

Hemolysis is the primary safety limitation: HC₅₀ values of 2–10 µM overlap with cytotoxic concentrations, making systemic free-peptide delivery problematic. Liposomal encapsulation reduces hemolysis by 3–5x while maintaining efficacy.

•

In vivo IP administration at 2 mg/kg every 48 hours produced 52% tumor volume reduction: in SKOV-3 ovarian xenografts without significant hematological toxicity — establishing proof-of-concept for peritoneal delivery.

•

Synergy with cisplatin: has been demonstrated (combination index <0.8) at sub-IC₅₀ concentrations of both agents, suggesting CyO1 may function as a chemosensitizer by disrupting drug efflux mechanisms.

•

The oral stability of CyO1: — >95% intact after 24 hours with trypsin, chymotrypsin, pepsin, and GluC — makes it theoretically suitable for oral delivery, opening applications for gut-localized infections and potentially gut tumors that no other peptide anticancer agent can address.

•

Key unanswered questions: include: whether CyO1 induces immunogenic cell death in immunocompetent models, how loop-grafted variants behave compared to native CyO1, and whether combination with checkpoint inhibitors produces durable antitumor responses.

•

CyO1 is a research compound: , not a clinical therapeutic. All protocols described here are for laboratory use. Synthesis remains technically demanding and expensive; cost reduction through improved folding or biosynthetic production is the key bottleneck for broader research access.

---

•

Gramicidin S | Buy Online | AMP Research Guide — Another cyclic peptide with membrane-active antimicrobial properties; useful structural comparison for cyclotide researchers.

•

Plitidepsin | Buy Online | Marine Anticancer Depsipeptide Guide — A marine-derived cyclic depsipeptide with anticancer activity; different mechanism but overlapping research applications.

•

Lunasin | Buy Online | Anti-Cancer & Anti-Inflammatory Guide — Another plant-derived peptide with anticancer properties; compare epigenetic vs. membrane-active mechanisms.

•

LL-37 Antimicrobial Peptide Guide — The leading human membrane-active antimicrobial peptide; direct mechanistic comparator for CyO1's antimicrobial applications.

•

Buy Plant-Derived Peptides | Skin Regeneration & Dermatology Research — Overview of the plant-derived peptide category with sourcing and research guidance.

Frequently Asked Questions

What is Cycloviolacin O1 and where does it come from?

Cycloviolacin O1 (CyO1) is a 29-amino-acid cyclic peptide isolated from Viola odorata (sweet violet). It belongs to the cyclotide class, characterized by a cyclic cystine-knot (CCK) topology with a Möbius-type backbone twist.

How does Cycloviolacin O1 kill cancer cells?

CyO1 disrupts cancer cell membranes by electrostatically docking to exposed phosphatidylserine, inserting its hydrophobic face into the lipid bilayer, and forming toroidal pores that cause osmotic collapse and cell lysis. It also triggers downstream caspase-3-mediated apoptosis.

What is the IC₅₀ of Cycloviolacin O1 against tumor cells?

IC₅₀ values range from approximately 0.7 µM (U-937 lymphoma) to 3.4 µM (MCF-7 breast cancer) at 72 hours, with a 4–14x selectivity window over normal human fibroblasts.

Is Cycloviolacin O1 stable to proteases?

Yes. The cyclic cystine-knot topology makes CyO1 exceptionally protease-resistant — >95% of the peptide remains intact after 24-hour incubation with trypsin, chymotrypsin, pepsin, and endoproteinase GluC under physiological conditions.

What is the main safety concern with Cycloviolacin O1?

Hemolysis. CyO1 lyses red blood cells at concentrations (HC₅₀ 2–10 µM) that overlap with its cytotoxic range, making systemic free-peptide delivery problematic. Liposomal or nanoparticle encapsulation reduces hemolytic activity by 3–5x.

What antimicrobial activity does Cycloviolacin O1 have?

CyO1 shows MIC values of 2–8 µM against Gram-positive organisms including MRSA (MIC 4 µM), and reduced preformed S. aureus biofilms by 68% at 8 µM over 24 hours. Gram-negative coverage is weaker (MIC >32 µM).

Has Cycloviolacin O1 been tested in animal models?

Yes. Intraperitoneal injection at 2 mg/kg every 48 hours for 3 weeks reduced SKOV-3 ovarian xenograft tumor volume by 52% in mice, with no significant hematological toxicity at that dose and schedule.

Can Cycloviolacin O1 be taken orally?

CyO1 has theoretical oral bioavailability due to its protease resistance — related cyclotides show detectable plasma levels after oral dosing in animal models. Human oral bioavailability data for CyO1 specifically has not been published, but the structural basis for oral stability is well-established.

cycloviolacin O1 buy onlinecycloviolacin O1 anticancer peptidecyclotide peptide researchViola odorata cyclotidecyclic cystine knot peptideplant derived anticancer peptidecycloviolacin O1 mechanism of actioncycloviolacin antimicrobial activitycyclotide MRSA researchmembrane active peptide cancer

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations

Looking for more? Buy peptides online from the #1 peptide research platform.